Psychological therapy for mood instability within bipolar spectrum disorder: a single-arm feasibility study of a dialectical behaviour therapy-informed approach by Wright, K et al.
RESEARCH Open Access
Psychological therapy for mood instability
within bipolar spectrum disorder: a single-
arm feasibility study of a dialectical
behaviour therapy-informed approach
Kim Wright1*, Gemma Palmer1, Mahmood Javaid2, Mohammod Mostazir3 and Tom Lynch4
Abstract
Background: We sought to evaluate the acceptability of a psychological therapy programme (Therapy for Inter-
episode Mood Variability in Bipolar Disorder (ThrIVe-B)) for individuals with ongoing bipolar mood instability and
the feasibility and acceptability of potential trial procedures. We also evaluated the performance of clinical and
process outcome measures and the extent to which the programme potentially represents a safe and effective
intervention.
Method: We conducted an open (uncontrolled) trial in which 12 individuals with a bipolar spectrum diagnosis
commenced the ThrIVe-B programme after completing baseline assessments. The programme comprised 16 group
skills training sessions plus individual sessions and a supporting smartphone application. Follow-up assessments
were at therapy end-point and 6months post-treatment.
Results: Nine participants completed treatment. Ten provided end-of-treatment data; of these, nine were satisfied
with treatment. Interviews with participants and clinicians indicated that the treatment was broadly feasible and
acceptable, with suggestions for improvements to content, delivery and study procedures. Exploration of change in
symptoms was consistent with the potential for the intervention to represent a safe and effective intervention.
Conclusions: Conducting further evaluation of this approach in similar settings is likely to be feasible, whilst patient
reports and the pattern of clinical change observed suggest this approach holds promise for this patient group.
Future research should include more than one study site and a comparison arm to address additional uncertainties
prior to a definitive trial.
Trial registration: Trial Registration: ClinicalTrials.gov NCT02637401; registered 22.12.15 (retrospectively registered).
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As well as experiencing episodes of depression and
mania or hypomania, some individuals with bipolar dis-
order report more short-lived, or less intense, fluctua-
tions in mood on an ongoing basis. Ongoing mood
instability is also present in cyclothymic disorder, which
by definition involves frequent, brief mood swings.
There is a clear need for effective interventions for this
inter-episode mood instability (IMI). First, it is relatively
common: the 12-month prevalence of cyclothymic dis-
order is around 1% [1], and whilst the prevalence of IMI
within bipolar I and II disorder is rarely reported, one
study found around half of participants in their sample
with euthymic bipolar I or II disorder to show marked
current mood instability [2]. Second, addressing IMI
may represent an opportunity for secondary prevention
and healthcare cost reduction as it is associated with risk
of developing a personally and financially costly full de-
pressive or manic episode [3]. Third, there is evidence
that IMI itself is associated with significant distress and
impairment in the form of increased psychiatric comor-
bidity (anxiety disorders, substance use [4]) and poorer
functioning [5, 6].
Currently, there is no established pharmacological
strategy for IMI; moreover, relatively few pharmaco-
logical treatment trials focus upon it as a feature of bipo-
lar disorders (BDs) [7–9]. Existing recommended
psychological therapies for bipolar disorder typically ad-
dress depression or relapse risk rather than IMI, which
is rarely measured in trials of these therapies. Whilst
there are a small number of published studies investigat-
ing psychological therapies for cyclothymic disorder
[10–12], none specifically addresses IMI across the full
bipolar spectrum as reflected in both therapy design and
inclusion criteria.
To address this treatment gap, we have taken an
existing psychological therapy that addresses mood in-
stability in personality disorders (dialectical behaviour
therapy (DBT) [13]) and adapted it for IMI. DBT dir-
ectly addresses “stable instability” of mood (whereby
variable mood is the expected pattern) and contains
both emotional acceptance techniques such as mind-
fulness and emotional change techniques. Neverthe-
less, some adaptations are likely to be necessary for
clients with IMI: standard DBT targets key processes
hypothesised to contribute to mood instability related
to negative emotion (e.g. anger, sadness), but does
not equip patients to manage hypomanic mood states.
In addition, the primary outcomes in trials of stand-
ard DBT (mainly around self-injury) do not address
key areas of concern for individuals with bipolar dis-
order, such as presence and persistence of depressive
and manic states. This suggests that bespoke develop-
ment and testing of this approach in this population
is required. Several studies have examined modified
versions of DBT as an intervention for bipolar dis-
order with encouraging results [14–17]; however,
none has been fully powered randomised controlled
trials in adults, none has specifically selected those
with IMI and none has included individuals across
the full bipolar spectrum. In response, we have devel-
oped a DBT-informed therapy programme adapted
for IMI (the ThrIVe-B programme).
Prior to conducting a randomised pilot trial of
ThrIVe-B, we wished to address uncertainties regard-
ing the acceptability of the intervention and of key
future trial procedures. This included recruitment of
this patient group, who are not specifically identified
by existing health care services. Case series evaluation
is commonly used as a first step to address such un-
certainties [18], as well as to conduct preliminary as-
sessment of safety in a small number of individuals.
Because our intervention is group-based and therefore
does not lend itself to traditional case series method-
ology, we conducted an uncontrolled (open) feasibility
study of two consecutive iterations of the programme.
Our aims were to ascertain (i) the likely acceptability
of the intervention to patients, to inform further
treatment development; (ii) the feasibility and accept-
ability of study procedures, to inform a future rando-
mised pilot trial; (iii) the extent to which any changes
in clinical and process outcome measures are consist-
ent with the intervention having potential as a safe
and effective approach for this client group (assessed
through pattern of improvement/deterioration in
symptoms, including suicidality, and incidence of ser-
ious adverse events resulting from trial involvement).
In addition, we sought to examine the performance of
candidate outcome measures in terms of pre-post
treatment correlations and potential sensitivity of the




Ours was an uncontrolled (open) trial with outcome
evaluation points post-treatment and 6months post-
treatment. The study protocol is supplied as an add-
itional file.
Participants
Participants were required to be aged 18 or above
and to have current bipolar mood instability, the def-
inition of this being informed by DSM-V criteria for
cyclothymic disorder (over the past 2 years numerous
periods with hypomanic symptoms that do not meet
criteria for a hypomanic episode and numerous pe-
riods with depressive symptoms that do not meet cri-
teria for a depressive episode, continuing into the
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past month), and to be willing to engage in psycho-
logical therapy that focusses primarily on ongoing
mood instability and its consequences. Because of the
focus upon IMI as a trait that occurs across the bipo-
lar spectrum, participants were required to meet
DSM-IV [19] criteria for a bipolar spectrum condition
(bipolar I disorder, bipolar II disorder, bipolar dis-
order not otherwise specified or cyclothymic
disorder).
Patients were not able to participate in the study if
they were currently experiencing mania or substance de-
pendence disorder, were at high risk of attempting sui-
cide (judged to be at immediate risk, according to the
local research centre risk assessment tool), were cur-
rently receiving other psychological therapy, potentially
placed other group members at significant risk (for ex-
ample, through reported history of physical violence in
similar settings) or lacked capacity to consent to re-
search participation. Individuals presenting with another
area of difficulty that the therapist and participant be-
lieved should be the primary focus of intervention (for
example, prominent symptoms of post-traumatic stress
disorder) were not included in the study, nor were indi-
viduals presenting with difficulties characteristic of bor-
derline personality disorder rather than bipolar disorder
(frequent and serious deliberate self-harm, marked dis-
turbance in ability to form or maintain interpersonal re-
lationships), as standard DBT is likely to be a more
appropriate intervention for this group.
Potential participants were identified and approached
by staff members in mental health assessment teams.
Other than assessment, short-term support and medica-
tion advice, participants were not receiving ongoing sec-
ondary mental health care support.
As this was the first formal investigation of this sub-
group, we did not pre-specify a target recruitment rate.
Instead, we sought to use the findings to estimate re-
cruitment rate for a subsequent controlled feasibility
study. Informally, we considered that a recruitment rate
of below two participants a month would be of concern
for future studies because this would result in a long
wait for participants to commence the group treatment.
We also surveyed clinicians from local mental health
teams about their view of the therapy approach. A total
of 10 clinicians participated in the survey, with four
completing a brief semi-structured interview.
Intervention
The intervention consisted of 16 sessions of group skills
training, supported by individual meetings of up to 30
min that occurred approximately monthly for each per-
son over the 4 months of group sessions. In addition,
there were two “booster” group sessions at 3 and 6
months post-intervention.
Content of group sessions was informed by DBT and
followed a modular format: mindfulness I (2 sessions),
emotion regulation (5), mindfulness II (2), distress toler-
ance (2), interpersonal effectiveness (4) and consolida-
tion (1). Content was developed in consultation with
individuals with personal experience of bipolar disorder
and followed five key principles of DBT: (i) clearly struc-
tured treatment; (ii) application of behavioural therapy;
(iii) emphasis on validation of emotional response; (iv)
dialectical stance, balancing acceptance and change; and
(v) integration of mindfulness practice [20]. Topics cov-
ered included skills for observing events, thoughts, emo-
tions and bipolar symptoms without reacting
impulsively, balancing lifestyle and activities to maximise
mood stability and healthy rather than hypomanic posi-
tive mood, skills for downregulating emotion and negoti-
ating interpersonal difficulties (which are often a
consequence and a trigger of bipolar mood swings).
The group therapy sessions were delivered by two
therapists. Individual sessions were with one of the two
therapists, ensuring that all clients had the opportunity
to meet separately with each therapist at least once dur-
ing the programme. Therapy was delivered within a spe-
cialist psychological therapies service for adults with
mood disorders.




All participants were individuals diagnosed by their clin-
ician as having (or probably having) bipolar or cyclothy-
mic disorder. In addition, diagnosis was assessed by the
research team using the structured clinical interview for
DSM-IV [21], supervised by a clinical psychologist expe-
rienced in the use of the SCID.
Primary outcome measures: acceptability and feasibility
Acceptability of the therapy was measured in terms of (i)
proportion of participants completing treatment (defined
as attending at least 50% of the 16 group therapy ses-
sions), (ii) participant ratings of treatment satisfaction,
(iii) qualitative analysis of semi-structured interviews
with participants at the end of therapy, (iv) clinician sat-
isfaction ratings and (v) qualitative analysis of semi-
structured interviews with clinicians. Overall participant
satisfaction with the treatment was rated on a scale from
1 (very dissatisfied) to 4 (very satisfied); these data were
collected as part of the standard service patient experi-
ence measure post-treatment. A more detailed measure
of participant satisfaction was developed specifically for
this study and asked participants, post-treatment and at
follow-up, to rate their satisfaction on a scale from 1
(not at all) to 4 (very much so) with therapy content,
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group aspect, smartphone app, length of treatment, fre-
quency of contact, fit with other commitments, dis-
charge process and the ThrIVe-B programme. Neither
measure has been externally validated.
Acceptability of the study procedures was addressed
through qualitative analysis of the participant interviews
and rates of completion of research measures. Feasibility
was assessed via recruitment rate and qualitative analysis
of interviews with clinicians.
Secondary outcome measures
Measures of symptoms Manic symptoms were assessed
using the 11-item, observer-rated Bech-Rafaelsen Mania
Rating Scale (BMRS) [22] pre- and post-intervention.
The BMRS has been shown to have adequate internal
consistency and construct validity. The Altman Scale for
Rating Mania (ASRM) [23], a five-item self-report meas-
ure of (hypo)manic symptom level, was completed on a
session-by-session basis during the intervention: scores
were used to inform and support therapy.
Depressive symptoms were measured using the nine-
item Patient Health Questionnaire (PHQ9) [24], a widely
used measure that can be used both to grade depressive
symptom severity and establish probable presence of a
major depressive episode pre- and post-intervention.
The 21-item Beck Depression Inventory, second edition
(BDI-II) [25] was also completed pre- and post-
intervention, as well as on a session-by-session basis and
at 6 months post-intervention.
Bipolar symptoms were also measured using the 16-
item Internal State Scale (ISS) [26], which produces
scores on four dimensions of depression, wellbeing, acti-
vation and perceived conflict.
Given high levels of anxiety amongst those with BD
[27], the seven-item Generalised Anxiety Disorder Scale
(GAD) [28] was used. As a general measure of psychi-
atric symptomatology, we included the 10-item Clinical
Outcomes in Routine Evaluation Scale (CORE-10) [29].
Measures of sense of personal recovery and quality of
life The 36-item Bipolar Disorder Recovery Question-
naire (BDRQ) [30] was included as a measure of sense of
personal recovery in people with bipolar disorder, as dis-
tinct from symptomatic or medical recovery. The BDRQ
has been found to have adequate internal consistency
and convergent validity. Finally, we included a measure
of quality of life developed to be specific to individuals
with bipolar disorder, the 12-item Brief Quality of Life
in Bipolar Disorder scale (QoL.BD) [31].
Clinical process measures Based upon the hypothesised
core mechanisms of action of our intervention, we in-
cluded measures of impulsive response to positive
emotion (UPPS-P Impulsive Behaviour Scale [32]),
avoidance behaviour (BADS: Behavioural Avoidance in
Depression Scale [33]), mindfulness skills (KIMS: Ken-
tucky Inventory of Mindfulness Skills [34]) and interper-
sonal functioning (IIP-32: Inventory of Interpersonal
Problems—short version [35]). We also measured prob-
lematic beliefs about bipolar mood states (Brief-HAPPI:
Brief Hypomanic Attitudes and Positive Predictions In-
ventory [36]) and a single-item asking about sense of fit
with the group as social identification with treatment
group may predict reduction of depression symptoms in
individuals with unipolar depression [37]. Participants
used a purpose-built smartphone application during part
of the therapy within which they rated their mood at
least once daily and viewed coping suggestions they had
pre-entered. Findings pertaining to the application are
not reported here.
Intervention and trial safety This was assessed through
examination of (i) rate of symptom deterioration (overall
and with respect to suicidality) and (ii) rate of serious
adverse events judged to be a consequence of the ther-
apy or trial.
Procedure
After giving written, informed consent to a member of the
study team, participants completed a research interview
including relevant sections of the SCID to determine study
eligibility. Eligible participants wishing to continue then
completed the acceptability, outcome and process mea-
sures. All participants used the monitoring app for 1 week
prior to the first group therapy session. Participants
returned completed BDI-II and ASRM measures to each
group therapy session. Mid-way through the programme,
participants completed the process measures.
Following the final group therapy session, participants
completed a post-treatment interview including the SCID
mood disorders section for the period since initial assess-
ment, and the acceptability, outcome and process measures.
Six months after the end of the intervention phase,
participants completed the SCID mood disorders section
for the period since the previous assessment, the BDI-II
and ASRM and measures of quality of life (QoL.BD), re-
covery (BDRQ) and acceptability of the intervention.
Sample size
We aimed to recruit sufficient numbers for two itera-
tions of the therapy programme, with each therapy
group containing between 4 and 8 participants.
Blinding
Because of the absence of a comparator arm, neither
participants nor assessors were blind to participant
allocation.
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Statistical methods
Descriptive statistics were used to summarise participant
flow through the study and responses on quantitative
measures of acceptability. To examine changes on clin-
ical and process measures, means and standard devia-
tions were calculated, as were effect sizes of change in
scores from pre- to post-treatment [(μ2 − μ1)/pre-treat-
ment SD]. For each participant, reliable change in their
scores from pre- to post-treatment was calculated using
the reliable change index (RCI: SEdiff = SD1√2 √1 − r)
[38]. Analyses were per protocol (PP: including only
those attending at least 50% of sessions) and intention to
treat (ITT), using all data available, regardless of treat-
ment received. Bivariate correlations were conducted to
examine pre-post correlations within measures.
Qualitative data were subjected to thematic analysis.
Transcripts from interviews with participants were
coded by one rater, and a preliminary thematic
framework developed. The transcripts were then
coded by a second rater using the framework. Dis-
crepancies in coding, and modifications to the frame-
work, were discussed and a joint framework agreed.
The transcripts were then recoded by rater 2 follow-
ing the agreed framework.
Transcripts from interviews with staff were subjected
to thematic analysis by a single rater and common
themes identified.
Results
Recruitment and participant flow
Recruitment and data collection took place between
January and July 2015 with follow-up ending in June
2016, when the final piece of data had been
collected.
Eighteen individuals either contacted the study dir-
ectly or gave consent for their clinician to pass their
details to the research team. A total of 15 participants
were assessed for eligibility; of these, three did not
continue with the study, one person being ineligible
to take part and two opting not to take part. Conse-
quently, 12 people commenced the intervention, a
rate of two participants entering the study per month
and nine completed it (defined as attending at least
50% of group therapy sessions). Reasons for non-
completion included change in work circumstances
(1), not finding the approach to be helpful/being too
unwell to attend (1) and unknown (1). The median
number of group therapy sessions attended for those
commencing treatment was 13/16 (range 3–16). Of
the 12 individuals commencing treatment, 10 com-
pleted the research follow-up assessments at post-
treatment and 6 months post-treatment. Recruitment
and retention information is displayed in Fig. 1.
Participant characteristics
Of the 12 individuals commencing therapy, 9 were fe-
male; the mean age of participants was 42 (SD 11). All
participants were of white British ethnicity; the majority
were married and in employment. Five were found to
meet criteria for bipolar I disorder, five for bipolar II dis-
order and two for bipolar disorder not otherwise speci-
fied. The majority of participants were prescribed
psychiatric medication. Table 1 gives details of partici-
pant characteristics.
Participant acceptability ratings
Nine out of 10 participants reported being mostly or
very satisfied with treatment at post-treatment, with all
reporting being at least slightly satisfied with the
ThrIVe-B programme at 6 months follow-up. The areas
associated with highest satisfaction were group-based
nature of the treatment, length of treatment, frequency
of contact with therapists and the referral and discharge
process. The area associated with the lowest satisfaction
was the use of the smartphone application. See Table 2
for acceptability ratings.
Qualitative information pertaining to acceptability
Three overarching themes were identified: engagement
in therapy, process of therapy and impact of therapy.
Each of these contained second and third-order sub-
themes (see Supplementary Material 1). The engagement
theme included valued aspects of the therapy delivery
and structure and potential areas for improvement. The
aspects mentioned most frequently by participants as
positive included the balance of individual and group
sessions and the presence of individual contact. All par-
ticipants gave opinions on the app, including suggestions
for improvements in delivery and content. Within the
process theme, all but one participant commented upon
the benefit of being in a group of people with similar ex-
periences, with individual participants also commenting
on specific aspects of this such as learning from others,
and the group itself being an incentive for attendance.
Two participants voiced disadvantages of the group as-
pect of the therapy, namely feeling different and isolated
from others and not wanting to hear about or share
problems. With regard to therapy content, all modules
were mentioned as helpful by at least one participant. As
well as learning skills, learning more about oneself and
having the space to reflect were seen as valuable. Where
difficulty or dissatisfaction the content of the therapy
was voiced, this was in terms of knowing the concepts,
but it being hard to apply in practice/in the moment,
techniques being less effective in severe mood states,
already using some of the ideas before coming to the
group and a sense that mood swings are not within per-
sonal control.
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In terms of the impact of therapy, the most commonly
cited changes in intrapersonal behaviour included in-
creased acceptance of the self, internal events and exter-
nal events; ability to step back from emotions and
situations; ability to make better choices (rather than
acting impulsively); and being able to let go of experi-
ences. The ability to observe others and see things from
their perspective was the most commonly endorsed as-
pect of interpersonal behavioural change. Participants
who commented upon impact on symptoms reported
symptoms persisting, but also symptom reduction and
stabilisation of mood. It is notable that some participants
endorsed both persistence of symptoms and improve-
ment or stabilisation. Four participants commented
upon a sense that therapy had prevented symptoms
worsening. Impact on relationships was described by
participants as including positive effects of change in
themselves on others around them and a sense of build-
ing better relationships. Some participants also commen-
ted that therapy impacted positively upon their
functioning at work.
Referrer and clinician feedback
All 10 staff considered the group format and length of
treatment acceptable and appropriately placed in the
care pathway and viewed DBT as an appropriate inter-
vention for this population. The use of the smartphone
application in the group was viewed least positively of all
Fig. 1 Study flow chart (adapted CONSORT diagram)
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aspects of the intervention. Overall, 9/10 clinicians were
“very much” satisfied with the programme as a treatment
option for their clients, and one “moderately”.
Common themes identified from the semi-structured in-
terviews were a distinction between different types of BD
and the treatments that best suit each type, the state of
current provision for this patient group in services, the
suitability of a group intervention for people with BD and
specific comments and recommendations for ThrIVe-B
groups. In summary, clinicians described the ThrIVe-B
approach as likely to be appropriate for people with bipolar
spectrum conditions who sought psychological and func-
tional support in the community or for those with cyclo-
thymic disorder and less appropriate for those tending to
become very unwell very quickly, resulting in hospital ad-
mission. Clinicians spoke of the limitations of the current
provision, acknowledging that people with BD are often ex-
cluded from primary care psychological therapies and that
those who do receive a service from secondary care are
more likely to be offered care coordination rather than
Table 1 Baseline characteristics of the sample
Variable Number (%) / Mean (SD)
Age (M (SD)) 42 (11)
Gender 9 (75%) female
3 (25%) male
Ethnicity 12 (100%) white British
Marital status 7 (58%) married
5 (42%) single
Employment status 8 (67%) employed
1 (8%) retired
3 (25%) unemployed
Research diagnosis 5 (42%) bipolar I disorder
5 (42%) bipolar II disorder
2 (17%) bipolar disorder NOS
% prescribed mood stabilising medication 7 (58%)
% prescribed antidepressant medication 7 (58%)
% prescribed any psychiatric medication 8 (67%)









How satisfied were you with the type of treatment that you received? 10 1–4 3.2
(0.92)
– – –


































Items are rated from 1 (not at all) to 4 (very much so) other than the first item which is rated from 1 (very dissatisfied) to 4 (very satisfied). Due to an error, 3
participants completed overall acceptability rating post-treatment, but did not complete the detailed measure
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psychological intervention. They all spoke positively about
the benefits of providing psychological interventions in a
group environment; however, they noted this would not
suit all participants.
Study and therapy safety
There was one serious adverse event (a participant tried to
end their life) 4 months after the end of the treatment phase
(2 months before the final follow-up point): this was judged
not to be a result of the therapy or the trial procedures.
As another means of assessing safety of the interven-
tion, we explored change in self-reported frequency of
suicidal ideation (score on item 9 of PHQ9) from base-
line to end of treatment. In no participants did this in-
crease: three participants reported no ideation at
baseline and this remained the case post-treatment; in
two participants, ideation was reported at baseline and
did not change; five participants reported ideation at
baseline but not at the end of treatment.
Secondary outcome measures
Symptoms, sense of personal recovery and quality of life
Mean scores on the clinical outcome measures at base-
line, post-therapy and at 6 months post-end of



























ITT 30.30 (11.23) 15.60 (10.81) 0.42 1.31 0, 3, 7 21.80 (13.03)
PP 29.67 (11.72) 13.00 (7.45) 0.44 1.42 0, 2, 7 19.78 (12.04)
PHQ9 18.25
(6.34)
ITT 17.50 (6.67) 10.00 (7.09) 0.64 1.12 0, 4, 6 –
PP 16.78 (6.65) 8.56 (5.75) 0.59 1.24 0, 3, 6
GAD7 13.92
(5.47)
ITT 12.90 (5.43) 4.90 (3.18) 0.11 1.47 0, 2, 8 –
PP 13.11 (5.71) 4.89 (3.37) 0.11 1.44 0, 2, 7
BMRS 4.08 (6.40) ITT 2.40 (2.59) 1.70 (2.54) 0.97 0.27 0, 10, 0 –
PP 2.56 (2.70) 1.89 (2.62) 0.97 0.25 0, 9, 0
ASRM1 3.75 (4.39) ITT 4.40 (4.55) 5.30 (2.11) 0.36 0.20 2, 6, 2 6.00 (4.27)
PP 4.67 (4.74) 5.67 (1.87) 0.31 0.21 2, 5, 2 6.33 (4.39)
CORE-10 20.08
(6.20)
ITT 19.80 (6.71) 12.30 (7.39) 0.30 1.12 1, 3, 6 –
PP 19.33 (6.95) 10.89 (6.25) 0.21 1.22 1, 3, 5
QoL.BD2 28.91
(8.35)
ITT 30.00 (6.61) 38.67 (7.86) 0.23 1.31 0, 5, 4 34.40 (10.50)



















179.00 (144.03) 0.57 0.38 0, 8, 2 –
PP 252.22
(147.88)







114.00 (72.60) 0.78 0.65 0, 7, 3 –
PP 195.56
(135.84)





ITT 108.00 (70.36) 144.00 (87.71) 0.82 0.51 0, 8, 2 –





ITT 96.00 (47.19) 66.00 (67.36) 0.57 0.64 1, 5, 4 –
PP 90.00 (45.83) 51.11 (51.10) 0.35 0.85 0, 5, 4
Nine participants completed 6months post-treatment follow-up
ITT intention-to-treat sample (n = 12), PP per protocol sample (n = 9), BDI-II Beck Depression Inventory—second edition, PHQ9 Patient Health
Questionnaire, GAD7 Generalised Anxiety Disorder Scale, BMRS Bech-Rafaelson Mania Rating Scale, ASRM Altman Scale for Rating Mania, CORE-
10 Clinical Outcomes in Routine Evaluation Scale, QoL.BD Brief Quality of Life in Bipolar Disorder Scale, BDRQ Bipolar Disorder Recovery
Questionnaire, ISS Internal State Scale
1Completed prior to session 1 of therapy
2ITT n = 11; PP n = 8
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intervention are given in Table 3. Also, displayed are
pre-post correlations for each measure and the number
of participants showing reliable improvement, reliable
deterioration and no change upon each clinical outcome
measure for both per protocol and ITT analyses.
As can be seen, mean levels of anxiety and depression
reported by participants were clinically significant at
baseline, with mean BDI-II score in the severe range,
mean PHQ9 score moderately severe, mean GAD7 score
moderate and general distress and impairment (as mea-
sured by the CORE-10) in the moderate to severe range.
In contrast, mean BRMS and ASRM scores fell in the
non-clinical range.
Mean score on the QoL-BD at baseline fell within one
standard deviation of mean score on this measure in a
sample of individuals with bipolar disorder prior to com-
mencing a psychoeducation intervention (35.356 [SD
10.10]) [39], whilst mean score on the BDRQ (sense of
personal recovery) fell more than one standard deviation
below mean score in a sample of individuals with bipolar
disorder who took part in the original measure valid-
ation study (2357.7 [SD 414.0]: Jones et al. [30]).
As a means of assessing the possible sensitivity of the
outcome measures to detect change in post-treatment,
we used the RCI. This indicated reliable improvement in
at least half of the participants on the following mea-
sures: BDI-II, PHQ9, GAD7, CORE, BDRQ (ITT ana-
lyses) and QoL-BD (PP analysis only). Without a
comparison group, it is not possible to infer any effect of
treatment upon scores on these measures; however, the
presence of reliable change in at least half of the sample
is consistent with the possibility that these measures
could be sensitive to treatment effects.
In contrast, for the majority of participants, no reliable
change was observed in scores on the Bech Mania Scale,
ASRM and ISS.
Use of the RCI and consideration of effect size also
allowed us to explore the extent to which patient out-
comes were consistent with this being a safe and effective
treatment. In almost all participants where change was ob-
served, this was in the direction of reliable improvement.
Whilst the current study design cannot test efficacy, this
finding supports a case for further investigation. Reliable
deterioration was observed on only three measures: the
ASRM (n = 2), BDRQ (n = 1) and CORE-OM (n = 1).
That this pattern was not observed across their scores on
other measures of symptoms and quality of life suggests
that there was not a subgroup of individuals upon which
the treatment may have had a marked deleterious effect.
In SCID interviews conducted at the end of treatment,
5/10 participants reported at least one episode of depres-
sion and 5/10 reported at least one episode of hypo-
mania since the baseline assessment, with 7/10 reporting
at least one episode of any type. Six months after the
end of treatment, 5/10 reported depression and 2/10
hypomania, with 7/10 reporting at least one episode of
any type. No participants reported experiencing mania
over the course of the study.
Clinical process measures
Table 4 gives mean scores on process measures at base-
line, midway through therapy and post-treatment, as










(deterioration, no change, improvement)
BADS total 71.44 (27.51) 100.00 (20.35) 0.37 1.04 0, 5, 4
KIMS_OB1 40.17 (9.68) 44.33 (7.53) 0.64 0.43 0, 5, 1
KIMS_DES1 26.33 (6.86) 28.50 (3.15) 0.65 0.32 0, 4, 2
KIMS_AW1 23.67 (8.59) 29.33 (8.16) 0.59 0.66 0, 4, 2
KIMS_AC1 21.50 (8.98) 25.67 (5.20) 0.23 0.46 0, 4, 2
HAPPI 2333.25 (821.02) 1497.94 (760.96) 0.25 1.02 1, 2, 6
IIP (n = 8) 58.44 (18.37) 49.75 (18.27) 0.56 0.51 0, 6, 2
UPPS-P
NU2
38.88 (5.84) 34.44 (8.31) 0.22 1.05 0, 4, 4
UPPS-P
PU2
45.88 (9.71) 37.56 (11.40) 0.04 0.85 0, 3, 5
UPPS-P
PM2
25.99 (6.22) 24.78 (5.19) 0.53 0.20 1, 7, 0
UPPS-P
SS2
30.88 (6.45) 30.22 (7.26) 0.66 0.27 0, 7, 1
UPPS-P
PR2
23.00 (6.76) 22.11 (4.96) 0.57 0.09 1, 6, 1
Group fit 2.38 (1.06) 3.78 (1.09) − .11 1.32 NA
n = 9 unless otherwise stated
BADS Behavioural Avoidance in Depression Scale, KIMS Kentucky Inventory of Mindfulness Skills, HAPPI Brief Hypomanic Attitudes and Positive
Predictions Inventory, IIP-32 Inventory of Interpersonal Problems—short version, UPPS-P UPPS-P Impulsive Behaviour Scale
1n = 6 completed post-treatment KIMS
2n = 8 completed both time points
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well as the results of reliable change analyses on per
protocol data. Reliable change was observed in at least
half of participants on the following measures: HAPPI,
UPPS-P NU and UPPS-P PU, and for all but one data
point, change was in the direction of reliable improve-
ment. Again, effect of treatment upon these scores can-
not be inferred; nevertheless, the presence of reliable
change in at least half of the sample on these measures
is consistent with the possibility that these measures
could be sensitive to treatment effects.
Discussion
This open feasibility trial represents the first attempt to
evaluate the potential of a DBT-informed approach for
individuals with bipolar mood instability occurring out-
side of full affective episodes. We sought to evaluate the
feasibility of recruiting participants to a trial of this na-
ture and the acceptability of the programme to those
who were offered it.
Conducting further evaluation of this approach appears
feasible (see Supplementary Material 2 for a summary of
findings). Given that recruitment was from only a small
number of mental health assessment teams over a 6-
month period, the rate of participants consented and eli-
gible for the trial per fortnight is commensurate with the
feasibility of a larger trial, using more diverse recruitment
sources. A recruitment rate of at least 2 participants per
month in a future feasibility randomised controlled trial
would allow two study sites to recruit 50 participants in
just over a year, adequate for feasibility assessment; this
trial could examine the impact of using additional referral
sources (such as self-referral and primary care) in prepar-
ation for a definitive trial. It also speaks to bipolar mood
instability being an aspect of BD that patients and clini-
cians believe deserves specific attention and treatment.
Furthermore, clinician feedback supports the acceptability
of this approach to potential referrers, and hence the feasi-
bility of future recruitment from mental health teams. In
terms of follow-up data collection, 83% of participants
starting treatment returned follow-up data at post-
treatment and 6months post-treatment, suggesting that
completeness of follow-up data in future trials is likely to
be at an acceptable level.
Overall, it appears that participants found the treat-
ment approach acceptable, with 75% of participants
completing treatment and only one participant dissatis-
fied at the end of the therapy period, with none dissatis-
fied at 6 months post-treatment. Further work is
required to determine what should constitute “treatment
completion” in terms of session attendance and the rate
of therapy completion that renders the intervention vi-
able from a health economics perspective. Examination
of the themes arising from in-depth interviews with par-
ticipants supported the value of the mode of delivery
and the therapy content, whilst some themes indicated
areas for improvement, for example, modifications to
the smartphone app to increase ease of use.
We also sought to examine the extent to which any
changes in outcome and process measures are con-
sistent with the intervention having potential as a safe
and effective approach for this client group. There
was no evidence for any participant showing a con-
sistent pattern of reliable deterioration in their scores
on the outcome measures, and it does not appear that
the intervention was associated with increased suicidal
thinking. It should be noted though that two partici-
pants did not complete the end of therapy outcome
measures and therefore their possible response to
treatment is unknown, although qualitative feedback
was provided by one of these participants upon exit-
ing therapy, and this indicated a positive view of the
sessions attended and their effects. The current design
is not able to test the efficacy of the intervention.
Nonetheless, the finding that, on measures of depres-
sion, anxiety, general psychiatric symptoms and sense
of personal recovery, at least half of participants
showed reliable improvement suggests future testing
of potential clinical benefit is indicated.
Finally, we sought to examine the performance of can-
didate outcome and process measures. Where reliable
change in a substantial number of individuals was ob-
served, this is consistent with these measures being sen-
sitive to treatment effects and supports their use in
future testing of this approach. No or little reliable
change was observed on measures of mania symptoms
and the Internal State Scale: it is not clear whether this
is a consequence of measure insensitivity or due to a
genuine absence of change. It is notable that mean levels
of mania symptoms in the sample were in the non-
clinical range at baseline, which have restricted the po-
tential for decrease on these measures. Amongst the
candidate process measures, those addressing impulsive
response to affect (UPPS-P positive and negative urgency
scales, and to some extent the BADS) and potentially
unhelpful beliefs about mood states showed the greatest
degree of reliable change across participants, supportive
of their use in future evaluations of this approach.
Although commensurate with early-stage testing of a
psychological intervention in a little-researched popula-
tion, our relatively small sample size and the use of a
single location and service in the delivery of the inter-
vention limit the generalisability of our findings. Also,
data on the typical patient population of the referring
services was not available, limiting our ability to com-
pare our sample with the service population. Including a
comparison condition in further feasibility testing with a
larger sample will be necessary in order to pilot the
likely design of a future definitive trial. In addition, this
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will permit blinding of assessors thus reducing potential
for bias. Furthermore, the current study did not select
participants on the basis of a severity threshold with re-
gard to IMI: future research should seek to incorporate
dimensional measurement of IMI to permit this.
In conclusion, the ThrIVe-B programme appears to be
broadly acceptable to both patients and their clinical
teams, with several aspects that could be improved. Con-
ducting further evaluation of this approach is likely to be
feasible. Following modification to the therapy
programme in line with the findings of the current
study, future research should seek to evaluate the feasi-
bility of a randomised controlled evaluation of the
ThrIVe-B programme.
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